Evaluation in Hematology and BCR-ABL Molecular Profiles in Patients with Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy


  • Muhammad Ihza Lisan Shidqi Department of Clinical/Medical Laboratory Science, Universitas Muhammadiyah Semarang, Indonesia
  • Budi Santosa Department of Clinical/Medical Laboratory Science, Universitas Muhammadiyah Semarang, Indonesia.
  • Muhamad Muslim Department of Medical Laboratory Technology, Universitas Borneo Lestari, Indonesia
  • Haitami Haitami Department of Medical Laboratory Technology, Poltekkes Kemenkes Banjarmasin, Indonesia




Chronic myeloid leukemia (CML) is a myeloproliferative malignancy due to the formation of the BCR-ABL fusion gene in chronic myeloid leukemia. This condition causes excessive cell proliferation, resulting in an increase in the number of leukocytes. Tyrosine Kinase Inhibitor (TKI) is a first-line therapy that helps reduce the percentage of the Breakpoint Cluster Region–Abelson (BCR-ABL) fusion gene in patients with chronic myeloid leukemia. This study was conducted to determine evaluation in the hematological profiles (hemoglobin levels, leukocyte counts, platelet counts) and molecular BCR-ABL in patients with chronic myeloid leukemia before and after 12 months of tyrosine kinase inhibitors therapy. This analytic observational study was administered using a cross-sectional design to in analyzing the medical records of CML patients who underwent TKI therapy at the Sub Specialist Polyclinic of Internal Medicine Hematology Oncology Ulin Banjarmasin Indonesia Regional Hospital from March 2021-April 2022. Statistical test was performed which analysis results showed that 12-month tyrosine kinase inhibitor therapy could increase the hemoglobin levels, decrease leukocyte counts, platelet counts as well as decreasing the percentage of BCR-ABL gene fusion in patients with chronic myeloid leukemia. In conclusion, evaluation of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia obtained significant differences in the hematological profiles and the molecular BCR-ABL. Further researchers are recommended to compare the type of tyrosine kinase inhibitor therapy between Imatinib and Nilotinib on the hematological and molecular profiles of BCR-ABL in patients with chronic myeloid leukemia with a larger sample count.


Alves, A. R., Lima, W. G., Nagai, M. M., Rodrigues, J. P. V., & Ayres, L. R. (2016). Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia. Brazilian Journal of Pharmaceutical Sciences, 52(4), 581–590. https://doi.org/10.1590/S1984-82502016000400001

Bhutani, N., Arora, D., & Bhutani, N. (2020). Hematological and Molecular Response Assessment of CP-CML Patients Treated with Imatinib : An Experience from a Tertiary Care Hospital in India. Galore International Journal of Health Sciences and Research, 5(June), 53–55.

Bintoro, S. U. Y. (2019). Chronic Myeloid Leukemia: Perkembangan Baru Dalam Tata Laksana Dan Implikasi Terhadap Ketahan Hidup (Vol. 53, Issue 9). Airlangga University Press.

Branford, S. (2020). Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica, 105(12), 2730–2737. https://doi.org/10.3324/haematol.2019.240739

Brümmendorf, T. H., Gambacorti-Passerini, C., Bushmakin, A. G., Cappelleri, J. C., Viqueira, A., Reisman, A., Isfort, S., & Mamolo, C. (2020). Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. Annals of Hematology, 99(6), 1241–1249. https://doi.org/10.1007/s00277-020-04018-1

Dia Rofinda, Z. (2012). Kelainan Hemostasis pada Leukemia. Jurnal Kesehatan Andalas, 1(2), 68–74. https://doi.org/10.25077/jka.v1i2.40

dos Reis, S. R. C., Quixadá, A. T. de S., Nunes, S. T., Cid, D. M. C., de Souza, J. H., da Costa, C. M. B. E., Silveira, C. B., Cid, D. A. C., & de Oliveira, M. F. C. (2013). Adherence to treatment with imatinib in chronic myeloid leukemia: A study of the first decade of responses obtained at a Brazilian hospital. Revista Brasileira de Hematologia e Hemoterapia, 35(3), 174–179. https://doi.org/10.5581/1516-8484.20130053

Efficace, F., Baccarani, M., Breccia, M., Cottone, F., Alimena, G., Deliliers, G. L., Baratè, C., Specchia, G., Di Lorenzo, R., Luciano, L., Turri, D., Martino, B., Stagno, F., Dabusti, M., Bergamaschi, M., Leoni, P., Simula, M. P., Levato, L., Fava, C., … Mandelli, F. (2013). Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia, 27(7), 1511–1519. https://doi.org/10.1038/leu.2013.51

Francis, J., Palaniappan, M., Dubashi, B., Pradhan, S. C., & Chandrasekaran, A. (2015). Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study. Journal of Pharmacology and Pharmacotherapeutics, 6(1), 30–33. https://doi.org/10.4103/0976-500X.149141

Gater, A., Heron, L., Abetz-Webb, L., Coombs, J., Simmons, J., Guilhot, F., & Rea, D. (2012). Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leukemia Research, 36(7), 817–825. https://doi.org/10.1016/j.leukres.2012.01.021

How, J., Venkataraman, V., & Hobbs, G. S. (2021). Blast and accelerated phase CML: room for improvement. Hematology (United States), 2021(1), 122–128. https://doi.org/10.1182/hematology.2021000240

Huang, X., Cortes, J., & Kantarjian, H. (2012). Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer, 118(12), 3123–3127. https://doi.org/10.1002/cncr.26679

Jabbour, E., & Kantarjian, H. (2020). Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. American Journal of Hematology, 95(6), 691–709. https://doi.org/10.1002/ajh.25792

Jbireal, J. & Azab, Azab & S, Alzahani & M, Elshareef (2019). Haematological and cytogenetic changes in CML patients treated with imatinib mesylate in Western Libya. Hematology & Transfusion International Journal, 7(3), 50–57. https://doi.org/10.15406/htij.2018.07.00205

Khazaal, M. S., Hamdan, F. B., & Al-Mayah, Q. S. (2019). Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients. Molecular Genetics and Genomic Medicine, 7(8), 1–9. https://doi.org/10.1002/mgg3.809

Kumar, S., Gupta, V. K., Bharti, A., Meena, L. P., Gupta, V., & Shukla, J. (2019). A study to determine the clinical, hematological, cytogenetic, and molecular profile in CML patient in and around Eastern UP, India. Journal of Family Medicine and Primary Care, 8(2), 169–170. https://doi.org/10.4103/jfmpc.jfmpc

Le, C. H. H. (2016). The prevalence of anemia and moderate-severe anemia in the US population (NHANES 2003-2012). PLoS ONE, 11(11), 1–14. https://doi.org/10.1371/journal.pone.0166635

Marin, D., Bazeos, A., Mahon, F. X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., Paliompeis, C., Latham, V., Foroni, L., Molimard, M., Reid, A., Rezvani, K., De Lavallade, H., Guallar, C., Goldman, J., & Khorashad, J. S. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28(14), 2381–2388. https://doi.org/10.1200/JCO.2009.26.3087

Menon, H. (2013). Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome. South Asian Journal of Cancer, 02(01), 038–043. https://doi.org/10.4103/2278-330x.105893

Nasser, A., Hussein, A., Chamba, C., Yonazi, M., Mushi, R., Schuh, A., & Luzzatto1, L. (2021). Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Advances, 5(5), 1403–1411. https://doi.org/10.1182/bloodadvances.2020002973

Okouango, N., Elira, D., & Ngolet, L. (2017). Adherence to imatinib in patients with chronic myeloid leukemia in the Congo. Austin Hematology, 2(1), 1–5.

Park, M., Park, C. J., Cho, Y. W., Jang, S., Lee, J. H., Lee, J. H., Lee, K. H., & Lee, Y. H. (2017). Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow. Experimental Hematology, 45(Cml), 56–63. https://doi.org/10.1016/j.exphem.2016.09.009

Press, R. D. (2010). Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy. The Oncologist, 15(7), 744–749. https://doi.org/10.1634/theoncologist.2010-0055

Rahem, R., Alaawad, A., & Kamoona, T. (2016). Evaluation of molecular monitoring and response milestone of patients with chronic myeloid leukemia to tyrosine kinase inhibitors in Middle Euphrates of Iraq. Iraqi Journal of Hematology, 5(2), 143. https://doi.org/10.4103/2072-8069.198080

Rajabto, W., Purba, T. B. G., & Chandika, V. (2022). Evaluation of Treatment Outcomes of Patients with Chronic Phase Chronic Myelogenous Leukemia (CML) to Imatinib: A Single Centre Experience 2010-2015 Period. Journal of Natural Science, Biology and Medicine.

Reksodiputro, A. H. (2014). Epidemiologic study and mutation profile of patients with Chronic Myeloid Leukemia (CML) in Indonesia. J Blood Disorders Transf, 5(8), 105.

Sholikah, T. A. (2017). Fusion gene bcr-abl : from etiopathogenesis to the management of Chronic Myeloid Leukemia. Indonesian Journal of Medicine and Health, 8, 29–37.

Sugiharta, P., & Anggoro, J. (2020). Gambaran Hasil Darah Rutin Penderita Leukemia Mieloid Kronis di Rumah Sakit Umum Daerah Provinsi Nusa Tenggara Barat. Jurnal Kedokteran, 9(1), 78–82.




How to Cite

Lisan Shidqi, M. I., Santosa, B., Muslim, M., & Haitami, H. (2022). Evaluation in Hematology and BCR-ABL Molecular Profiles in Patients with Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy. Medical Laboratory Technology Journal, 8(2), 200–208. https://doi.org/10.31964/mltj.v8i1.484




Most read articles by the same author(s)